-

Arrivo Bio to Present and Meet with Investors at the 37th Annual Piper Sandler Healthcare Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio today announced that members of its executive management team will participate in the 37th Annual Piper Sandler Healthcare Conference, being held on December 2–4 in New York, New York. The team will host investor meetings and present an overview of the Company’s business and pipeline.

Presentation Details:

  • Date: Thursday, December 4, 2025
  • Time: 1:30-1:50pm ET
  • Participants: Steve Butts, Co-founder and Chief Executive Officer, and Greg Rigdon PhD, Senior Vice President of Scientific Affairs

About Arrivo Bio
Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

Contacts

Media:
Alexis Feinberg
Alexis.Feinberg@icrhealthcare.com

Investor:
Aman R. Patel, CFA & Adanna G. Alexander, PhD
Aman.Patel@icrhealthcare.com & Adannna.Alexander@icrhealthcare.com

Arrivo Bio


Release Versions

Contacts

Media:
Alexis Feinberg
Alexis.Feinberg@icrhealthcare.com

Investor:
Aman R. Patel, CFA & Adanna G. Alexander, PhD
Aman.Patel@icrhealthcare.com & Adannna.Alexander@icrhealthcare.com

More News From Arrivo Bio

Arrivo Bio to Participate in Fireside Chat at the Piper Sandler Virtual CNS Symposium

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio, a clinical-stage biopharmaceutical company developing first-of-its-kind medicines targeting the root cause of hard-to-treat diseases, today announced that Steve Butts, Co-founder and Chief Executive Officer, and Joel Raskin, Chief Medical Officer will participate in a virtual fireside chat discussing forvisirvat, the company’s novel potential treatment for major depressive disorder, at the Piper Sandler Virtual CNS Symposium on Friday, August 14th...

Clinical Data on Arrivo Bio’s RABI-767 program to be presented at EPC 2026 Annual Meeting

MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinical data on Arrivo Bio’s RABI-767 program will be presented at the 58th European Pancreatic Club (EPC)/International Association of Pancreatology (IAP) Annual Meeting, taking place June 24–27, 2026 in Istanbul, Turkey. The presentation will highlight RABI-767, a small molecule pancreatic lipase inhibitor in development for patients with predicted severe acute pancreatitis (SAP). RABI-767 is designed to inhibit pancreatic lipase activity and interrupt the...

Arrivo Bio to Present Clinical Data on Forvisirvat at 2026 ASCP Annual Meeting

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving both an oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29 in Miami, Florida. The presentations will highlight Forvisirvat (SP-624), Arrivo’s first-in-class oral activator of the SIRT6 enzyme, currently in a Phase 2b/3 study for major depressive disorder, with data read out expected later this year. Prior Phase 2 data demonstrated a signal of efficacy...
Back to Newsroom